Online Provision of BRCA1 and BRCA2 Health Information: A Search Engine Driven Systematic Web-Based Analysis
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Organisation Groups
2.2. Search Strategy
2.3. Website Selection
2.4. Data Extraction and Website Content Evaluation
3. Results
3.1. Information Provision: UKOs and JCOs
Organisation (Total Number) | ||
---|---|---|
BRCA Information Format | JCO (n = 16) | UKO (n = 45) |
Dedicated webpage | 2 (13%) | 10 (22%) |
Mentioned on webpage | 2 (13%) | 14 (31%) |
Mention in published media | 8 (50%) | 31 (69%) |
Outreach talk or workshop | 3 (19%) | 4 (9%) |
Online forum | 0 | 4 (9%) |
Signposting | 10 (63%) | 28 (62%) |
Support group | 1 (6%) | 8 (18%) |
Telephone helpline | 0 | 6 (13%) |
3.2. Genetic Testing Providers (GTPs)
3.3. Domain 1: Accessibility
3.4. Domain 2: Scope
Number of Websites with: | UKO | JCO | GTP | Total | |||||
---|---|---|---|---|---|---|---|---|---|
n = 45 | % | n = 16 | % | n = 18 | % | n = 79 | % | ||
Accessibility | ≤3 mouse clicks | 37 | 82.2 | 14 | 87.5 | 15 | 83.3 | 66 | 83.5 |
A search bar present | 38 | 84.4 | 15 | 93.8 | 14 | 77.8 | 67 | 84.8 | |
Accessibility score of 1 | 31 | 68.9 | 13 | 81.3 | 12 | 66.7 | 56 | 71 | |
Scope | >50% total items addressed | 14 | 31.1 | 3 | 18.8 | 12 | 66.7 | 29 | 36.7 |
>50% total BRCA information | 13 | 28.9 | 5 | 31.3 | 10 | 55.6 | 28 | 35.4 | |
Scope score of 1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Depth | BRCA-associated cancers (BC and OC, and/or ProC, PanC, or melanoma) | 23 | 51.1 | 4 | 25.0 | 10 | 55.6 | 37 | 46.8 |
All BRCA carrier risk management options | 6 | 13.3 | 3 | 18.8 | 5 | 27.8 | 14 | 17.7 | |
Difference in carrier frequency in AJ vs non-AJ populations | 0 | 0.0 | 1 | 6.3 | 0 | 0.0 | 1 | 1.3 | |
Explanation of BRCA inheritance | 8 | 17.8 | 3 | 18.8 | 9 | 50.0 | 20 | 25.3 | |
Increased cancer risks for BRCA carriers for each gene and/or multiple cancers | 16 | 35.6 | 1 | 6.3 | 6 | 33.3 | 23 | 29.1 | |
Signposting to >2 resources | 11 | 24.4 | 4 | 25.0 | 3 | 16.7 | 18 | 22.8 | |
Depth score of 1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | |
Accuracy | Accurate BRCA-associated cancers | 38 | 84.4 | 8 | 50.0 | 16 | 88.9 | 62 | 78.5 |
Accurate BRCA carrier risk management options | 18 | 40.0 | 3 | 18.8 | 7 | 38.9 | 28 | 35.4 | |
Accurate carrier frequency in AJ population | 5 | 11.1 | 5 | 31.3 | 5 | 27.8 | 15 | 19.0 | |
Accurate carrier frequency in the general population | 0 | 0.0 | 3 | 18.8 | 2 | 11.1 | 5 | 6.3 | |
Accurate increased risks for BRCA: carriers female BC and OC | 13 | 28.9 | 2 | 12.5 | 3 | 16.7 | 18 | 22.8 | |
Accurate increased risks for BRCA: carriers male BC, ProC, PanC, & melanoma | 7 | 15.6 | 2 | 12.5 | 1 | 5.6 | 10 | 12.7 | |
Accuracy score of 1 | 0 | 0.0 | 1 | 6.3 | 0 | 0.0 | 1 | 1.3 | |
Quality | DISCERN overall score of 5 | 2 | 4.4 | 0 | 0.0 | 0 | 0.0 | 2 | 2.5 |
Quality score of 1 | 2 | 4.4 | 0 | 0.0 | 0 | 0.0 | 2 | 2.5 | |
Overall score >3.5 out of 5 | 5 | 11.1 | 2 | 12.5 | 2 | 11.1 | 9 | 11.4 |
3.5. Domain 3: Depth
3.6. Domain 4: Accuracy
3.7. Domain 5: Quality
3.8. Combined Scores across All Five Domains
4. Discussion
4.1. Findings
4.2. Strengths and Weaknesses
4.3. Interpretation
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Chen, J.; Bae, E.; Zhang, L.; Hughes, K.; Parmigiani, G.; Braun, D.; Rebbeck, T.R. Penetrance of Breast and Ovarian Cancer in Women Who Carry a BRCA1/2 Mutation and Do Not Use Risk-Reducing Salpingo-Oophorectomy: An Updated Meta-Analysis. JNCI Cancer Spectr. 2020, 4, pkaa029. [Google Scholar] [CrossRef]
- Li, S.; Silvestri, V.; Leslie, G.; Rebbeck, T.R.; Neuhausen, S.L.; Hopper, J.L.; Nielsen, H.R.; Lee, A.; Yang, X.; McGuffog, L.; et al. Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. J. Clin. Oncol. 2022, 40, 1529–1541. [Google Scholar] [CrossRef]
- Nyberg, T.; Frost, D.; Barrowdale, D.; Evans, D.G.; Bancroft, E.; Adlard, J.; Ahmed, M.; Barwell, J.; Brady, A.F.; Brewer, C.; et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. Eur. Urol. 2020, 77, 24–35. [Google Scholar] [CrossRef]
- Gentile, D.; Losurdo, A.; Sagona, A.; Zuradelli, M.; Gatzemeier, W.; Barbieri, E.; Testori, A.; Errico, V.; Bianchi, P.; Biondi, E.; et al. Surgical management of BRCA-mutation carriers: A single institution experience. Eur. J. Surg. Oncol. 2022, 48, 1706–1712. [Google Scholar] [CrossRef]
- Slade, E.; Berg, L.; Dworzynski, K.; Manchanda, R.; Guideline, C. Ovarian cancer: Identifying and managing familial and genetic risk-summary of new NICE guidance. BMJ 2024, 385, q807. [Google Scholar] [CrossRef]
- Wei, X.; Sun, L.; Slade, E.; Fierheller, C.T.; Oxley, S.; Kalra, A.; Sia, J.; Sideris, M.; McCluggage, W.G.; Bromham, N.; et al. Cost-Effectiveness of Gene-Specific Prevention Strategies for Ovarian and Breast Cancer. JAMA Netw. Open 2024, 7, e2355324. [Google Scholar] [CrossRef] [PubMed]
- Domchek, S.M.; Friebel, T.M.; Singer, C.F.; Evans, D.G.; Lynch, H.T.; Isaacs, C.; Garber, J.E.; Neuhausen, S.L.; Matloff, E.; Eeles, R.; et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010, 304, 967–975. [Google Scholar] [CrossRef] [PubMed]
- Heemskerk-Gerritsen, B.A.M.; Jager, A.; Koppert, L.B.; Obdeijn, A.I.; Collee, M.; Meijers-Heijboer, H.E.J.; Jenner, D.J.; Oldenburg, H.S.A.; van Engelen, K.; de Vries, J.; et al. Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. Treat. 2019, 177, 723–733. [Google Scholar] [CrossRef] [PubMed]
- NICE. Familial Breast Cancer: Full Guideline; NICE: Manchester, UK, 2017. [Google Scholar]
- Nelson, H.D.; Fu, R.; Zakher, B.; Pappas, M.; McDonagh, M. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA 2019, 322, 868–886. [Google Scholar] [CrossRef]
- Michaan, N.; Leshno, M.; Cohen, Y.; Safra, T.; Peleg-Hasson, S.; Laskov, I.; Grisaru, D. Preimplantation genetic testing for BRCA gene mutation carriers: A cost effectiveness analysis. Reprod. Biol. Endocrinol. 2021, 19, 153. [Google Scholar] [CrossRef]
- NHS England. Clinical Commissioning Policy: Genetic Testing for BRCA1 and BRCA2 Mutations; NHS England: London, UK, 2015. [Google Scholar]
- Manchanda, R.; Burnell, M.; Gaba, F.; Desai, R.; Wardle, J.; Gessler, S.; Side, L.; Sanderson, S.; Loggenberg, K.; Brady, A.F.; et al. Randomised trial of population-based BRCA testing in Ashkenazi Jews: Long-term outcomes. BJOG Int. J. Obstet. Gynaecol. 2020, 127, 364–375. [Google Scholar] [CrossRef] [PubMed]
- Manchanda, R.; Burnell, M.; Loggenberg, K.; Desai, R.; Wardle, J.; Sanderson, S.C.; Gessler, S.; Side, L.; Balogun, N.; Kumar, A.; et al. Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. J. Med. Genet. 2016, 53, 472–480. [Google Scholar] [CrossRef]
- Manchanda, R.; Legood, R.; Burnell, M.; McGuire, A.; Raikou, M.; Loggenberg, K.; Wardle, J.; Sanderson, S.; Gessler, S.; Side, L.; et al. Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing. J. Natl. Cancer Inst. 2015, 107, 380. [Google Scholar] [CrossRef] [PubMed]
- Manchanda, R.; Sideris, M. Population-based genetic testing for cancer susceptibility genes: Quo vadis? BJOG Int. J. Obstet. Gynaecol. 2023, 130, 125–130. [Google Scholar] [CrossRef]
- NHS. Jewish Community’s NHS BRCA Screening Programme. Available online: https://nhsjewishbrcaprogramme.org.uk/ (accessed on 8 February 2024).
- Manchanda, R.; Loggenberg, K.; Sanderson, S.; Burnell, M.; Wardle, J.; Gessler, S.; Side, L.; Balogun, N.; Desai, R.; Kumar, A.; et al. Population testing for cancer predisposing BRCA1/BRCA2 mutations in the Ashkenazi-Jewish community: A randomized controlled trial. J. Natl. Cancer Inst. 2015, 107, 379. [Google Scholar] [CrossRef]
- Venkatesan, P. BRCA testing launched for people of Jewish ancestry in England. Lancet Oncol. 2024, 25, 284. [Google Scholar] [CrossRef] [PubMed]
- Yin, K.; Zhou, J.; Singh, P.; Wang, J.; Braun, D.; Hughes, K.S. Search Behavior Regarding Cancer Susceptibility Genes Using a Clinical Decision Support Tool for Gene-Specific Penetrance: Content Analysis. JMIR Cancer 2021, 7, e28527. [Google Scholar] [CrossRef]
- Eurostat. Digital Economy and Society Statistics—Households and Individuals; Eurostat: Luxembourg, 2022. [Google Scholar]
- Hall, J.A.; Gertz, R.; Amato, J.; Pagliari, C. Transparency of genetic testing services for ‘health, wellness and lifestyle’: Analysis of online prepurchase information for UK consumers. Eur. J. Hum. Genet. 2017, 25, 908–917. [Google Scholar] [CrossRef] [PubMed]
- Uter, W.; Eversbusch, C.; Gefeller, O.; Pfahlberg, A. Quality of Information for Skin Cancer Prevention: A Quantitative Evaluation of Internet Offerings. Healthcare 2021, 9, 229. [Google Scholar] [CrossRef]
- Pattenden, T.A.; Raleigh, R.A.; Pattenden, E.R.; Thangasamy, I.A. Quality and readability of online patient information on treatment for erectile dysfunction. BJUI Compass 2021, 2, 412–418. [Google Scholar] [CrossRef]
- Sansevere, M.E.; White, J.D. Quality Assessment of Online Complementary and Alternative Medicine Information Resources Relevant to Cancer. Integr. Cancer Ther. 2021, 20, 15347354211066081. [Google Scholar] [CrossRef] [PubMed]
- Murtaza, F.; Shirreff, L.; Huang, L.N.; Jacobson, M.; Jarcevic, R.; Christakis, M.K. Quality and readability of online health information on menopausal hormone therapy in Canada: What are our patients reading? Menopause 2021, 29, 54–62. [Google Scholar] [CrossRef]
- Charnock, D.; Shepperd, S.; Needham, G.; Gann, R. DISCERN: An instrument for judging the quality of written consumer health information on treatment choices. J. Epidemiol. Community Health 1999, 53, 105–111. [Google Scholar] [CrossRef] [PubMed]
- The DISCERN Instrument. Available online: http://www.discern.org.uk/index.php (accessed on 16 May 2023).
- Kuchenbaecker, K.B.; Hopper, J.L.; Barnes, D.R.; Phillips, K.A.; Mooij, T.M.; Roos-Blom, M.J.; Jervis, S.; van Leeuwen, F.E.; Milne, R.L.; Andrieu, N.; et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA 2017, 317, 2402–2416. [Google Scholar] [CrossRef] [PubMed]
- Dorling, L.; Carvalho, S.; Allen, J.; González-Neira, A.; Luccarini, C.; Wahlström, C.; Pooley, K.A.; Parsons, M.T.; Fortuno, C.; Wang, Q.; et al. Breast Cancer Risk Genes—Association Analysis in More than 113,000 Women. N. Engl. J. Med. 2021, 384, 428–439. [Google Scholar] [CrossRef]
- Grzymski, J.J.; Elhanan, G.; Morales Rosado, J.A.; Smith, E.; Schlauch, K.A.; Read, R.; Rowan, C.; Slotnick, N.; Dabe, S.; Metcalf, W.J.; et al. Population genetic screening efficiently identifies carriers of autosomal dominant diseases. Nat. Med. 2020, 26, 1235–1239. [Google Scholar] [CrossRef] [PubMed]
- Roa, B.B.; Boyd, A.A.; Volcik, K.; Richards, C.S. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat. Genet. 1996, 14, 185–187. [Google Scholar] [CrossRef] [PubMed]
- Menon, U.; Gentry-Maharaj, A.; Burnell, M.; Singh, N.; Ryan, A.; Karpinskyj, C.; Carlino, G.; Taylor, J.; Massingham, S.K.; Raikou, M.; et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A randomised controlled trial. Lancet 2021, 397, 2182–2193. [Google Scholar] [CrossRef] [PubMed]
- UK National Screening Committee. Adult Screening Programme: Ovarian Cancer. Available online: https://view-health-screening-recommendations.service.gov.uk/ovarian-cancer/ (accessed on 15 July 2023).
- Kearns, B.C.J.; Whyte, S.; Calvert, N.; Preston, L. An Economic Evaluation of the Cost-Effectiveness of Screening for Ovarian Cancer Amongst Postmenopausal Women Who Are Not at High Risk of Ovarian Cancer; School of Health and Related Research (ScHARR), University of Sheffield: Sheffield, UK, 2016. [Google Scholar]
- UK Cancer Genetics Group. UKCGG One-Page Gene-Specific Management Guidelines. Available online: https://www.ukcgg.org/information-education/ukcgg-leaflets-and-guidelines/ (accessed on 9 April 2024).
- Zeldman, J. Taking Your Talent to the Web: A Guide for the Transitioning Designer; New Riders: Indianapolis, IN, USA, 2001. [Google Scholar]
- Laubheimer, P. The 3-Click Rule for Navigation Is False. Available online: https://www.nngroup.com/articles/3-click-rule/ (accessed on 16 May 2023).
- Porter, J. Testing the Three-Click Rule. 16 April 2003. Available online: https://articles.centercentre.com/three_click_rule/ (accessed on 17 May 2024).
- Statista. Market Share of Leading Search Engines in the United Kingdom. Available online: https://www.statista.com/statistics/280269/market-share-held-by-search-engines-in-the-united-kingdom/ (accessed on 12 June 2023).
- Chitika Insights. The Value of Google Result Positioning; Chitika, Inc.: Westborough, MA, USA, 2013. [Google Scholar]
- Jørgensen, K.J.; Gøtzsche, P.C. Presentation on websites of possible benefits and harms from screening for breast cancer: Cross sectional study. BMJ 2004, 328, 148. [Google Scholar] [CrossRef]
- Dawson, J.Q.; Davies, J.M.; Ingledew, P.A. Quality of Online Information Regarding Cervical Cancer. Cureus 2020, 12, e9511. [Google Scholar] [CrossRef]
- Lerman, C.; Biesecker, B.; Benkendorf, J.L.; Kerner, J.; Gomez-Caminero, A.; Hughes, C.; Reed, M.M. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J. Natl. Cancer Inst. 1997, 89, 148–157. [Google Scholar] [CrossRef] [PubMed]
- Allen, C.G.; Roberts, M.; Andersen, B.; Khoury, M.J. Communication About Hereditary Cancers on Social Media: A Content Analysis of Tweets About Hereditary Breast and Ovarian Cancer and Lynch Syndrome. J. Cancer Educ. 2020, 35, 131–137. [Google Scholar] [CrossRef] [PubMed]
- Sankar, P.; Wolpe, P.R.; Jones, N.L.; Cho, M. How do women decide? Accepting or declining BRCA1/2 testing in a nationwide clinical sample in the United States. Community Genet. 2006, 9, 78–86. [Google Scholar] [CrossRef] [PubMed]
- Manchanda, R.; Burnell, M.; Gaba, F.; Sanderson, S.; Loggenberg, K.; Gessler, S.; Wardle, J.; Side, L.; Desai, R.; Brady, A.F.; et al. Attitude towards and factors affecting uptake of population-based BRCA testing in the Ashkenazi Jewish population: A cohort study. BJOG Int. J. Obstet. Gynaecol. 2019, 126, 784–794. [Google Scholar] [CrossRef] [PubMed]
- Sobocan, M.; Chandrasekaran, D.; Sideris, M.; Blyuss, O.; Fierheller, C.; Kalra, A.; Sia, J.; Miller, R.E.; Mills-Baldock, T.; Crusz, S.M.; et al. Patient decision aids in mainstreaming genetic testing for women with ovarian cancer: A prospective cohort study. BJOG Int. J. Obstet. Gynaecol. 2023, 131, 848–857. [Google Scholar] [CrossRef] [PubMed]
- Bender, J.L.; Jimenez-Marroquin, M.C.; Jadad, A.R. Seeking support on facebook: A content analysis of breast cancer groups. J. Med. Internet Res. 2011, 13, e16. [Google Scholar] [CrossRef] [PubMed]
- Burke, W.C.J.; Bowen, D.; Lowry, D.; Durfy, S.; McTiernan, A.; Andersen, M.R. Genetic counseling for women with an intermediate family history of breast cancer. Am. J. Med. Genet. 2000, 90, 361–368. [Google Scholar] [CrossRef]
- Metcalfe, K.A.; Poll, A.; O’Connor, A.; Gershman, S.; Armel, S.; Finch, A.; Demsky, R.; Rosen, B.; Narod, S.A. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation. Clin. Genet. 2007, 72, 208–217. [Google Scholar] [CrossRef]
- Lieberman, S.; Lahad, A.; Tomer, A.; Cohen, C.; Levy-Lahad, E.; Raz, A. Population screening for BRCA1/BRCA2 mutations: Lessons from qualitative analysis of the screening experience. Genet. Med. 2017, 19, 628–634. [Google Scholar] [CrossRef]
- Stacey, D.; Legare, F.; Lewis, K.; Barry, M.J.; Bennett, C.L.; Eden, K.B.; Holmes-Rovner, M.; Llewellyn-Thomas, H.; Lyddiatt, A.; Thomson, R.; et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev. 2017, 4, CD001431. [Google Scholar] [CrossRef]
- Kaphingst, K.A.; McBride, C.M.; Wade, C.; Alford, S.H.; Brody, L.C.; Baxevanis, A.D. Consumers’ use of web-based information and their decisions about multiplex genetic susceptibility testing. J. Med. Internet Res. 2010, 12, e41. [Google Scholar] [CrossRef] [PubMed]
- Torr, B.; Jones, C.; Choi, S.; Allen, S.; Kavanaugh, G.; Hamill, M.; Garrett, A.; MacMahon, S.; Loong, L.; Reay, A.; et al. A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot. J. Med. Genet. 2022, 59, 1179–1188. [Google Scholar] [CrossRef] [PubMed]
- NICE. Ovarian Cancer: Identifying and Managing Familial and Genetic Risk; Draft for consultation; NICE: Manchester, UK, 2023. [Google Scholar]
- Vicente, E.P.; De Faria, S.E.E.; Almeida, A.B.L.; Yamada, P.A.; Lucena, T.F.; Silva, T.M.; Bernuci, M.P. Cervical Cancer Prevention on Instagram: Content and Social Interaction Analysis of Brazilian Accounts. Asian Pac. J. Cancer Prev. 2022, 23, 3043–3049. [Google Scholar] [CrossRef] [PubMed]
Domain | Description of Scoring |
---|---|
Accessibility | Count the amount of clicks
Score = |
Scope | Number of questions answered/total number of questions
Score = |
Depth | Included questions: BRCA-associated cancers
Score = |
Accuracy * | Included questions: BRCA-associated cancers
Score = |
Quality | DISCERN score from final question (Q16). Score calculation Score = |
Organisation ID | Genes Tested | Who Orders the Test? | Cost of Test | Does the Cost Include Counselling? | Type of Counselling |
---|---|---|---|---|---|
GTP_160 | 61 gene panel (including BRCA1 and BRCA2) | HCP or DTC | Unknown | Unknown | Provided by individuals doctor/clinician |
GTP_161 | AJ pathogenic variants and other SNPs | DTC | £149 | No | Unknown |
GTP_162 | 9 gene panel (including BRCA1 and BRCA2) | DTC | £1400 | Yes | Pre- and post-test |
GTP_163 | 21, 14 or 3 gene panel (including BRCA1, BRCA2) | DTC | £490 | Yes | Post-test |
GTP_164 | BRCA1 and BRCA2 only | HCP | $0 (for >75% individuals covered by insurance) | No | Unknown |
GTP_165 | Unknown | DTC | Unknown | Unknown | Pre-test |
GTP_166 | BRCA1 and BRCA2 or AJ PVs only | HCP | Unknown | Unknown | Unknown |
GTP_167 | Unknown but mentions BRCA1 and BRCA2 | HCP | Unknown | Unknown | Unknown |
GTP_168 | BRCA1 and BRCA2 | HCP or DTC | Unknown | Yes | Pre- and post-test |
GTP_169 | 30 gene panel including BRCA1 and BRCA2 | DTC | £249 | No | Unknown |
GTP_170 | WGS or breast panel (9 genes including BRCA1 and BRCA2) | DTC for WGS | WGS £4995 | Yes | Pre- and post-test |
GTP_171 | BRCA1 and BRCA2 | HCP | From £650 | No | Recommended but not provided |
GTP_172 | BRCA1 and BRCA2 | DTC | £1985 | Yes | Pre- and post-test |
GTP_173 | 51 gene panel including BRCA1 and BRCA2 | DTC | £1300 | Yes | Pre- and post-test |
GTP_174 | WGS | DTC | £299–£2164 + £275 | No | Unknown |
GTP_175 | BRCA1 and BRCA2 | DTC | £606 | Unknown | Unknown |
GTP_176 | 30 gene panel including BRCA1 and BRCA2 | HCP | $258.95 | Unknown | Post test |
GTP_177 | BRCA1 and BRCA2 full gene or only AJ PVs | HCP | Unknown | Unknown | Pre- and post-test |
Domain Median (IQR) | ||||||
---|---|---|---|---|---|---|
Organisation Type | Accessibility | Scope | Depth | Accuracy | Quality | Total |
JCO | 1 (0) | 0.2 (0.3) | 0 (0.2) | 0.1 (0.4) | 0.2 (0.05) | 1.5 (0.7) |
UKO | 1 (0.5) | 0.3 (0.3) | 0.2 (0.2) | 0.3 (0.3) | 0.4 (0.4) | 1.9 (1) |
GTP | 1 (0.5) | 0.7 (0.3) | 0.3 (0.3) | 0.3 (0.2) | 0.4 (0.4) | 2.2 (0.9) |
Overall | 1 (0.5) | 0.3 (0.4) | 0.2 (0.3) | 0.3 (0.2) | 0.2 (0.4) | 1.9 (1.1) |
Female Cancer Risk % (95%CI) | Male Cancer Risk % (95%CI) | |||
---|---|---|---|---|
Cancer Type | BRCA1 | BRCA2 | BRCA1 | BRCA2 |
Breast | 72% (65–79%) | 69% (61–77%) | 0.4% (0.1–1.5%) | 4% (2–8%) |
Ovarian | 44% (36–53%) | 17% (11–25%) | NA | NA |
Prostate | NA | NA | Not elevated | 27% (21–35%) |
Pancreatic | Not elevated | 2% (1–4%) | Not elevated | 3% (2–5%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gootzen, T.A.; Kalra, A.; Sarig, K.; Sobočan, M.; Oxley, S.G.; Dworschak, N.; Georgiannakis, A.; Glynou, S.; Taniskidi, A.; Ganesan, S.; et al. Online Provision of BRCA1 and BRCA2 Health Information: A Search Engine Driven Systematic Web-Based Analysis. Cancers 2024, 16, 2324. https://doi.org/10.3390/cancers16132324
Gootzen TA, Kalra A, Sarig K, Sobočan M, Oxley SG, Dworschak N, Georgiannakis A, Glynou S, Taniskidi A, Ganesan S, et al. Online Provision of BRCA1 and BRCA2 Health Information: A Search Engine Driven Systematic Web-Based Analysis. Cancers. 2024; 16(13):2324. https://doi.org/10.3390/cancers16132324
Chicago/Turabian StyleGootzen, Tamar A., Ashwin Kalra, Katrina Sarig, Monika Sobočan, Samuel George Oxley, Nina Dworschak, Ariadni Georgiannakis, Sevasti Glynou, Angeliki Taniskidi, Subhasheenee Ganesan, and et al. 2024. "Online Provision of BRCA1 and BRCA2 Health Information: A Search Engine Driven Systematic Web-Based Analysis" Cancers 16, no. 13: 2324. https://doi.org/10.3390/cancers16132324
APA StyleGootzen, T. A., Kalra, A., Sarig, K., Sobočan, M., Oxley, S. G., Dworschak, N., Georgiannakis, A., Glynou, S., Taniskidi, A., Ganesan, S., Ferris, M., Legood, R., Eeles, R., Evans, D. G. R., Fierheller, C. T., & Manchanda, R. (2024). Online Provision of BRCA1 and BRCA2 Health Information: A Search Engine Driven Systematic Web-Based Analysis. Cancers, 16(13), 2324. https://doi.org/10.3390/cancers16132324